Schrödinger

The lowest AI centrality grade in this category, and it is not a criticism so much as an accurate reading of what is being bought. The differentiating asset is physics, not machine learning: FEP+ free energy perturbation, Glide docking, Desmond molecular dynamics and Jaguar quantum chemistry are simulation engines built on more than 30 years of R&D, and they run without any model. Machine learning is real but layered on top, principally through the LiveDesign ML module for training and deploying property prediction models and through ML triage ahead of expensive physics calculations. The company states its position openly, that machine learning is most useful paired with physics based methods rather than treated as a substitute, and that refusal to inflate the AI claim is itself a candour benchmark in a category where the incentive runs the other way. Buyers should read this grade as a description of the mechanism, not of the quality.

The platform is a design environment for human chemists rather than an autonomous designer, which is the correct posture for a licensed tool and structurally limits the autonomy question. LiveDesign is explicitly collaborative, presenting physics based and machine learning calculations alongside experimental data so that medicinal chemists prioritize compounds before committing to synthesis. The decision to make a molecule stays with the customer's scientists. Held at B rather than A because no published disclosure was located on confidence thresholds, prediction reliability bands, or guidance on when a computed result should not be relied upon, which is the disclosure that would let a buyer calibrate trust in the output.

Among the strongest in the index on this axis. The methods are published and independently benchmarked across a large peer reviewed literature rather than described in marketing terms, product documentation and a knowledge base are publicly reachable, a Python API is published, and the company runs free and certificated courses that teach the underlying theory including a dedicated course on free energy calculations with FEP+. Named methodological advances are described specifically rather than generically, for example FEP+ Pose Builder as an integrated pipeline feature. A customer can read how the calculation works, reproduce it, and disagree with it.

Evidence exists at both the platform and the asset level, which is rare here. At asset level, the Nimbus originated TYK2 inhibitor zasocitinib (TAK-279), designed using the platform, advanced into Phase III, and the company's own SGR-1505 MALT1 inhibitor received FDA Fast Track designation for relapsed or refractory Waldenstrom macroglobulinemia with initial Phase 1 data reported at the EHA Annual Congress. At platform level the installed base is the evidence: the software is used across the top 20 pharmaceutical companies by revenue and in more than 70 countries, with published customer case studies including Morphic Therapeutic's alpha4beta7 integrin inhibitor. Caveat for buyers: widely cited figures for cycle time or synthesis reduction come from case studies and vendor materials rather than controlled comparisons, so treat magnitude claims as illustrative.

Not applicable in the provider sense and rated accordingly rather than penalized. The platform operates on molecular structures, simulation output and experimental chemistry data, with no patient records in the workflow. The analogous stewardship question for this buyer is protection of proprietary compound structures and target information, which is addressed through deployment architecture and contract rather than through a PHI policy.

Not applicable. Customers are pharmaceutical, biotechnology, industrial and academic research organizations licensing simulation software, not covered entities handing over protected health information, so no business associate relationship arises.

No SOC 2, ISO 27001 or equivalent attestation was located in public materials, and no trust center was found. This matters commercially even without PHI in scope, because customers place proprietary chemistry into the environment and that chemistry is often the most valuable IP the organization holds. The practical mitigation available here is architectural rather than attested: the software can be downloaded and run on customer controlled infrastructure, which removes the question rather than answering it. A buyer with a security review requirement should expect to run it through the license agreement.

Correctly structured for this category: the software platform is not a regulated medical device and is not presented as one, while regulatory engagement is real at the asset level. SGR-1505 holds FDA Fast Track designation for relapsed or refractory Waldenstrom macroglobulinemia and is in clinical development, SGR-3515 is a disclosed Wee1/Myt1 program, and a platform designed molecule from a partner program reached Phase III. Buyers should note that Fast Track designation is a development and review process mechanism, not an approval or a finding of efficacy.

No AI governance framework or model bias disclosure was located. The domain relevant bias question is chemical rather than demographic: whether trained property prediction models inherit the coverage limits of the data they were trained on and therefore perform worse in underexplored chemical space or on underrepresented target classes. The physics based engines are comparatively insulated from that failure mode by construction, which is a genuine architectural argument the company does not appear to make in governance terms.

Not applicable in the provider sense. There is no EHR touchpoint and no clinical workflow surface. The domain equivalent is research informatics interoperability, and here the story is genuinely strong: LiveDesign is positioned as an enterprise informatics layer unifying physics calculations, machine learning predictions and experimental data across discovery teams, and in January 2026 Lilly TuneLab workflows were made available inside LiveDesign with LiveDesign named a priority interface for participating biotech companies.

Better disclosed than most of this category because the product is genuinely licensed software rather than a partnership. A public release download portal and documented local installation mean the platform can run on customer controlled infrastructure, so proprietary structures need not leave the organization, and cloud scale execution is available for large virtual screens and ensemble calculations. Held at B because no explicit data residency terms, tenancy model or regional hosting commitments were located in public materials.

The Artrya precedent applies: a public listing forces disclosure that private peers can decline. As a Nasdaq registrant (SDGR) the company files software revenue, customer metrics, pipeline spend and risk factors on a regular cadence, maintains a public investor relations site with press releases and presentations, and publishes its end user license agreement, terms of use and other policies openly. There is still no published rate card for the software, and enterprise licensing is quoted through sales, so this is transparency of the business rather than of the price. Even so it is the most inspectable commercial surface in this category.

The broadest coverage in this category by a wide margin. Within life science the platform spans small molecule discovery (structure prediction and target enablement, hit discovery, hit to lead and lead optimization, formulation) and mixed modalities including antibody design, peptide discovery, enzyme engineering, bifunctional degraders and TCR modeling. A parallel materials science line covers polymers, organic electronics, energy storage, thin film processing, catalysis and metals and ceramics. Users span the top 20 pharmaceutical companies, biotech, academia and government laboratories across more than 70 countries.